Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

NCT07149363 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

DRUG: Durvalumab 50 MG/ML

Sponsor

Alliance Foundation Trials, LLC.

Collaborators

[object Object]